Drug · CHEMBL34259

METHOTREXATE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. METHOTREXATE. Drugs and targets, record CHEMBL34259. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL34259

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: METHOTREXATE; ChEMBL
ChEMBL ID: CHEMBL34259; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Ebetrex, Emtexate high-pot, Emtexate pf, Jylamvo, Maxtrex, Metoject, Nordimet, Otrexup, Otrexup pfs, Rasuvo, Reditrex, Zlatal; ChEMBL
Other names: (r)-methotrexate, ADX-2191, Amethopterin, CL 14377, CL-14377, D-amethopterin, D-methotrexate, EMT-25299, Jylamvo, Methotrexate, (r)-, Methotrexate, d-, Methotrexatum, Methylaminopterin, Metotrexato, NSC-740, R-9985, R-methotrexate; ChEMBL
Other form: METHOTREXATE SODIUM, CHEMBL3244648; Drugs and targets
DrugBank: DB00563; DrugBank
InChIKey: FBOZXECLQNJBKD-ZDUSSCGKSA-N; ChEMBL
Open Targets' highest stage: Approval, for 15 of its 258 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
DHFR	Dihydrofolate reductase	Dihydrofolate reductase inhibitor	INHIBITOR	https://conductscience.org/library/genes/1719

Source ChEMBL

Diseases258

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
rheumatoid arthritis	Approval	DailyMed, EMA Human Drugs and PMDA	265	254	https://conductscience.org/library/drugs?q=MONDO_0008383
acute lymphoblastic leukemia	Approval	DailyMed	199	195	https://conductscience.org/library/drugs?q=MONDO_0004967
primary central nervous system lymphoma	Phase 3	ClinicalTrials.gov	74	74	https://conductscience.org/library/drugs?q=MONDO_0002571
breast cancer	Approval	DailyMed	56	54	https://conductscience.org/library/drugs?q=MONDO_0007254
non-Hodgkin lymphoma	Approval	DailyMed	43	42	https://conductscience.org/library/drugs?q=MONDO_0018908
psoriasis	Approval	DailyMed and EMA Human Drugs	41	32	https://conductscience.org/library/drugs?q=MONDO_0005083
lymphoblastic lymphoma	Phase 3	ClinicalTrials.gov	29	29	https://conductscience.org/library/drugs?q=MONDO_0000873
osteosarcoma	Phase 3	ClinicalTrials.gov	29	29	https://conductscience.org/library/drugs?q=MONDO_0009807
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	28	28	https://conductscience.org/library/drugs?q=MONDO_0018874
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	22	22	https://conductscience.org/library/drugs?q=MONDO_0018905

1 to 10 of 258Source Open Targets

See all 258 diseases

Trials1,373

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01190930	Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma	Phase 3	9,350	2020-06-23	methotrexate	Its name	ClinicalTrials.gov
NCT02883049	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	Phase 3	5,949	2024-03-12	methotrexate	Its name	ClinicalTrials.gov
NCT00103285	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Phase 3	5,377	2018-07-11	methotrexate	Its name	ClinicalTrials.gov
NCT01594333	Cardiovascular Inflammation Reduction Trial	Phase 3	4,786	2020-07-24	methotrexate	Its name	ClinicalTrials.gov
NCT00075725	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Phase 3	3,154	2015-08-06	methotrexate	Its name	ClinicalTrials.gov
NCT01146652	Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)	Phase 3	2,023	2022-01-24	methotrexate	Its name	ClinicalTrials.gov
NCT00408005	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Phase 3	1,895	2019-06-20	methotrexate	Its name	ClinicalTrials.gov
NCT02889796	Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Phase 3	1,759	2021-01-19	methotrexate	Its name	ClinicalTrials.gov
NCT01061736	Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients	Phase 2/3	1,675	2017-06-28	methotrexate	Its name	ClinicalTrials.gov
NCT00134030	Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma	Phase 3	1,334	2023-06-07	methotrexate	Its name	ClinicalTrials.gov

1 to 10 of 1,373

See all 1,373 trials

Comparisons in its trials309

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29)	4,378 of 4,609	258 of 362	4,971	NCT00103285	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event or Any Coronary Revascularization	278 of 2,391	288 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Coronary Revascularization	190 of 2,391	205 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Events	170 of 2,391	167 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization	201 of 2,391	207 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event, Coronary Revascularization, Hospitalization for Congestive Heart Failure or All Cause Mortality	344 of 2,391	345 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Hospitalization for Congestive Heart Failure	48 of 2,391	53 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With All-cause Mortality	96 of 2,391	83 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: deaths from any cause	96 of 2,391	83 of 2,395	4,786	NCT01594333	Trial comparisons
Methotrexate vs Placebo: Number of Subjects With Hospitalization for Unstable Angina That Led to Unplanned Coronary Revascularization	41 of 2,391	50 of 2,395	4,786	NCT01594333	Trial comparisons

1 to 10 of 309

See all 309 comparisons in its trials

Papers from its trials1,280

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42263998	RESULT	2	PubMed
41807108	RESULT	1	PubMed
39471440	RESULT	1	PubMed
38772677	RESULT	1	PubMed
37953417	RESULT	1	PubMed
37908308	RESULT	1	PubMed
37294447	RESULT	1	PubMed
37141547	RESULT	1	PubMed
36749914	RESULT	1	PubMed
36701644	RESULT	1	PubMed

1 to 10 of 1,280

See all 1,280 papers from its trials

Tests in its trials11

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Trail Making Test A	4	0	ConductCognition
Trail Making Test B	4	0	ConductCognition
Verbal Fluency	4	0	ConductCognition
Verbal Learning	3	0	ConductCognition
Complex Figure Copy and Recall	2	0	ConductCognition
Clock Vigilance Test	1	1	ConductCognition
Continuous Performance Test	1	1	ConductCognition
Digit Span Test	1	0	ConductCognition
Go/No-Go Task	1	1	ConductCognition
Simon Task	1	1	ConductCognition

1 to 10 of 11

See all 11 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL34259

GET https://conductscience.org/api/drugs/v1/CHEMBL34259/diseases?page=2

API reference For AI assistants